Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Pre-Market Trading 04-09 06:23:59 EDT

1.16

+0.02

+1.75%

盘前1.11

-0.05-4.31%

04:47 EDT

High1.31	Low1.12	Vol818.74K
Open1.30	D1 Closing1.14	Amplitude16.67%
Mkt Cap37.14M	Tradable Cap21.37M	Total Shares32.02M
T/O996.11K	T/O Rate4.44%	Tradable Shares18.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":1.16,"timestamp":1744142400000,"preClose":1.14,"halted":0,"volume":818741,"hourTrading":{"tag":"盘前","latestPrice":1.11,"preClose":1.16,"latestTime":"04:47 EDT","volume":1578,"amount":1810.6999278,"timestamp":1744188462014},"delay":0,"floatShares":18422748,"shares":32017179,"eps":-2.192125,"marketStatus":"Pre-Market Trading","change":0.02,"latestTime":"04-09 06:23:59 EDT","open":1.3,"high":1.31,"low":1.12,"amount":996111.9858767,"amplitude":0.166667,"askPrice":1.46,"askSize":100,"bidPrice":1.11,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.192125,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.16,"preHourTrading":{"tag":"盘前","latestPrice":1.11,"preClose":1.16,"latestTime":"04:47 EDT","volume":1578,"amount":1810.6999278,"timestamp":1744188462014},"postHourTrading":{"tag":"盘后","latestPrice":1.2299,"preClose":1.16,"latestTime":"18:58 EDT","volume":1910,"amount":2254.0025,"timestamp":1744153135061},"volumeRatio":2.4550411423102774,"impliedVol":0.2802,"impliedVolPercentile":0.1143},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"2526825604","title":"BRIEF-Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA Resubmission - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526825604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526825604?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 05:11","pubTimestamp":1744146686,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA Resubmission - SEC FilingApril 8  - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS INC - FDA ACKNOWLEDGES RECEIPT OF OUTLOOK THERAPEUTICS' BLA RESUBMISSION - SEC FILINGOUTLOOK THERAPEUTICS INC - FDA SETS PDUFA GOAL DATE OF AUGUST 27, 2025 - SEC FILINGOUTLOOK THERAPEUTICS - FDA DETERMINED CLASS 2 REVIEW FOR OUTLOOK THERAPEUTICS' BLA FOR ONS-5010- SEC FILINGSource text: [ID:n0001558370-25-004606]Further company coverage: OTLK.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2526182588","title":"Outlook Therapeutics Inc - FDA Acknowledges Receipt of Outlook Therapeutics' Bla Resubmission - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526182588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526182588?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 05:01","pubTimestamp":1744146084,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2525816026","title":"Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2525816026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525816026?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 22:25","pubTimestamp":1744122333,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said Tuesday the resubmission of its biologics license application for ONS-5010, an investigational ophthalmic formulation for the treatment of wet age-related macular degeneration, was accepted by the US Food and Drug Administration.The agency's classification of the application as a class 2 review means that there will be a six-month review period from the date of resubmission, the company said.Outlook said the FDA has set a Prescription Drug User Fee Act goal date of Aug. 27, by which it must respond.The company also said it plans to brand the treatment as Lytenava in the US if approved by the agency, adding that it expects to receive 12 years of regulatory exclusivity.The shares were up over 9% in recent trading.Price: 1.25, Change: +0.11, Percent Change: +9.56","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823434583.USD","IE00BMPRXR70.SGD","BK4566","BK4534","BK4575","IE0004445239.USD","LU2458330169.SGD","IE00BMPRXN33.USD","LU1803068979.SGD","GFS","BK4554","BK4612","LU0081259029.USD","LU0198837287.USD","LU0823434740.USD","BK4585","LU1303367103.USD","LU0642271901.SGD","LU2458330243.SGD","LU0109392836.USD","LU0823421416.USD","OTLK","BK4141","BK4139","BK4614","BK4512","LU2360106780.USD","LU1880398471.USD","BK4605","BK4573","BK4543","LU2054465674.USD","LENZ","LU2098885051.SGD","LU1988902786.USD","BK4529","LU1951200564.SGD","LU0056508442.USD","LU0390134368.USD","LU1242518857.USD","LU1923623000.USD","IE0009356076.USD","AMD","LU0823421333.USD","LU0889565833.HKD","LU0082616367.USD","LU1316542783.SGD","BK4588","LU1852331112.SGD","IE00B5949003.HKD"],"gpt_icon":0},{"id":"2525890153","title":"BRIEF-Outlook Therapeutics® Announces Acceptance Of Biologics License Application By U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2525890153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525890153?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:27","pubTimestamp":1744118836,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces Acceptance Of Biologics License Application By U.S. FDAApril 8 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS ANNOUNCES ACCEPTANCE OF BIOLOGICS L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2525892609","title":"Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2525892609","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525892609?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:51","pubTimestamp":1744116695,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission of the Biologic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-by-u-s-fda-for-ons-5010?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-by-u-s-fda-for-ons-5010?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OTLK","LENZ","BK4007"],"gpt_icon":0},{"id":"2521249419","title":"BRIEF-Outlook Therapeutics Files Prospectus Covering Offer &  Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2521249419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521249419?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 05:12","pubTimestamp":1742505135,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Files Prospectus Covering Offer &  Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common StockMarch 20  - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS FILES PROSPECTUS COVERING OFFER &  RESALE BY SELLING STOCKHOLDERS OF UP TO 21.7 MILLION SHARES OF COMMON STOCK- SEC FILINGFurther company coverage: OTLK.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q3152:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2516810302","title":"Outlook Therapeutics files to sell 7.07M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2516810302","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516810302?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 05:40","pubTimestamp":1740778808,"startTime":"0","endTime":"0","summary":"16:39 EST Outlook Therapeutics (OTLK) files to sell 7.07M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-files-to-sell-7-07m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-files-to-sell-7-07m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK","BK4139","LENZ"],"gpt_icon":0},{"id":"2514329189","title":"Outlook Therapeutics Inc - FDA Decision Expected Within Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329189?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:05","pubTimestamp":1740747900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA3FGFHX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2514291843","title":"Outlook Therapeutics® Re-Submits Biologics License Application for Ons-5010 as a Treatment for Wet Amd to the U.S. Food and Drug Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2514291843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514291843?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:05","pubTimestamp":1740747900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA3FGFHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2512910816","title":"Outlook Therapeutics Inc : Guggenheim Cuts Target Price to $10 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2512910816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512910816?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 19:29","pubTimestamp":1739964557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3PA0O0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2512153977","title":"Outlook Therapeutics Is Maintained at Neutral by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512153977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512153977?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:07","pubTimestamp":1739876820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OTLK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 06:07 ET (11:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","OTLK"],"gpt_icon":0},{"id":"2512515829","title":"Outlook Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2512515829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512515829?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:04","pubTimestamp":1739876688,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nAZN3E7SHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2512539071","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2512539071","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512539071?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 19:00","pubTimestamp":1739876400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Allegion Public Ltd                               4Q      1.75    5:30 AM. ·Baidu Inc. Sp ADR                                 4Q      1.97        BMO. ·Donnelley Fncl Sols                               4Q       .49    7:00 AM. ·Exp Intl of Washg                                 4Q      1.43    8:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDNS","DFIN","CAKE","SBLK","BNL","NEO","MDT","CVNA","SON","ESI","CYH","FOUR","HLMN","VMI","TCMD","FMAO","WGS","WTTR","SPNS","HSBC","RBA","AIP","BELFA","TBRG","IFF","CLVT","TX","ADI","FLS","LZB","BHC","IOSP","BORR","OTLK","CF","ACVA","CVI","HALO","VTMX","FOLD","ANET","AWK","AGI","FELE","CLH","MGY","SEVN","FLR","CE","BLCO"],"gpt_icon":0},{"id":"2511873696","title":"Outlook Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2511873696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511873696?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 22:32","pubTimestamp":1739543526,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryOutlook Therapeutics Inc OTLK.OQ reported quarterly adjusted earnings of 72 cents per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL8N3P51EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK"],"gpt_icon":0},{"id":"2511693288","title":"BRIEF-Outlook Therapeutics Reports Financial Results For First Quarter Of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2511693288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511693288?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 22:07","pubTimestamp":1739542070,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 Feb 14 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER FISCA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA66KLRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2511966774","title":"Outlook Therapeutics Inc -Qtrly Shr $0.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2511966774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511966774?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 21:05","pubTimestamp":1739538302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA66KLRB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2511667744","title":"Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511667744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511667744?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 21:05","pubTimestamp":1739538302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA66KLRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2510857025","title":"Outlook Therapeutics Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2510857025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510857025?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 21:57","pubTimestamp":1739195827,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc  expected to post a loss of77cents a share - Earnings Preview Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL8N3P11CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK"],"gpt_icon":0},{"id":"2508916680","title":"BRIEF-Outlook Therapeutics Inc - Enters Securities Purchase Agreement With Avondale Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2508916680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508916680?lang=en_us&edition=full_marsco","pubTime":"2025-02-01 07:30","pubTimestamp":1738366215,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Inc - Enters Securities Purchase Agreement With Avondale CapitalOutlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS INC - ENTERS SECURITIES PURCHASE AGREEMENT WITH AVONDALE CAPITALOUTLOOK THERAPEUTICS INC - ISSUES UNSECURED CONVERTIBLE PROMISSORY NOTE OF $33.1 MILLIONSource text: [ID:n0001104659-25-008146]Further company coverage: OTLK.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nFWN3OR2BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2508990430","title":"Outlook Therapeutics Inc - Issues Unsecured Convertible Promissory Note of $33.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2508990430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508990430?lang=en_us&edition=full_marsco","pubTime":"2025-02-01 05:40","pubTimestamp":1738359650,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nFWN3OR2BS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0492},{"period":"1month","weight":-0.2215},{"period":"3month","weight":-0.4679},{"period":"6month","weight":-0.7652},{"period":"1year","weight":-0.8759},{"period":"ytd","weight":-0.3862}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.117155},{"month":2,"riseRate":0.444444,"avgChangeRate":0.160578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.13976},{"month":5,"riseRate":0.625,"avgChangeRate":0.151955},{"month":6,"riseRate":0.375,"avgChangeRate":-0.036511},{"month":7,"riseRate":0.555556,"avgChangeRate":0.021804},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.135567},{"month":9,"riseRate":0.444444,"avgChangeRate":0.026948},{"month":10,"riseRate":0.444444,"avgChangeRate":0.175694},{"month":11,"riseRate":0.111111,"avgChangeRate":-0.160695},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.106019}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction